Eribulin is one of the few recommended chemotherapies for locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). We systematically searched MEDLINE Ovid, Cochrane Library, IPA, CINAHL, Web of Science and ProQuest Dissertations for studies evaluating eribulin versus non-eribulin regimens in LABC/MBC till January 15, 2021. Primary effectiveness and safety outcomes were overall survival (OS) and adverse events (AE), respectively. Hazard ratios (HR) and relative risks (RR) with 95 % confidence intervals (CIs) were calculated using fixed or random-effects meta-analyses. Of 1183 publications identified, 13 studies were included in this review. Eribulin based therapy showed significantly increased OS [HR (95 % CI) = 0.77 (0.67−0.88)] compared to non-eribulin in both main and sensitivity analyses, as well as subgroup analyses according to receptor expression and line of therapy. Incidence of all-grade neutropenia was the only significant AE in eribulin than non-eribulin groups. Eribulin has a manageable toxicity profile and provides significant survival benefit in LABC/MBC patients.

艾日布林是少数推荐用于局部晚期乳腺癌 (LABC) 或转移性乳腺癌 (MBC) 的化疗之一。我们系统地检索了 MEDLINE Ovid、Cochrane 图书馆、IPA、CINAHL、Web of Science 和 ProQuest Dissertations，以了解在 2021 年 1 月 15 日之前评估 LABC/MBC 中艾日布林与非艾日布林方案的研究。主要有效性和安全性结果是总生存期 (OS) 和不良事件（AE），分别。使用固定或随机效应荟萃分析计算具有 95% 置信区间 (CI) 的风险比 (HR) 和相对风险 (RR)。在确定的 1183 篇出版物中，本综述纳入了 13 项研究。在主要和敏感性分析中，与非艾日布林相比，基于艾日布林的治疗显示出显着增加的 OS [HR (95 % CI) = 0.77 (0.67−0.88)]，以及根据受体表达和治疗线进行亚组分析。与非艾日布林组相比，艾日布林组中唯一显着的 AE 是全级别中性粒细胞减少症的发生率。艾日布林具有可控的毒性特征，并在 LABC/MBC 患者中提供显着的生存益处。